Skip to content

Korea Equity Lens

  • About
  • IR Room
  • Research
    • Semiconductors
    • Bio & Healthcare
    • Defense
    • EV & Battery
    • Automotive
    • Energy
    • Robotics
    • Shipbuilding
  • Toggle search form
  • [Research] SK hynix (000660 / SKHY) – Mirae Asset | ADR Listing · Valuation Gap · Re-rating / 2026-03-25 Research
  • [Research] Hanwha Ocean (042660) – DS Investment & Securities | Low-Price Mix Reduction · Merchant Margin Step-Up · MASGA & Defense Pipeline / 2026-04-28 Research
  • [Research] SK hynix (000660 / SKHY) – Kiwoom | Commodity Memory Pricing · Supply Constraints · Earnings Surge / 2026-05-11 Research
  • [Research] SK hynix (000660 / SKHY) – Yuanta | AI Inference · Enterprise SSD · Cash Flow / 2026-01-29 Research
  • [Research] LigaChem Biosciences (141080) – Mirae Asset Securities | Clinical Readouts · Pipeline Valuation · SOTP / 2026-01-26 Research
  • [Research] LigaChem Biosciences (141080) – Yuanta Securities | Payload Chemistry · Safety Profile · Differentiation / 2025-05-22 Research
  • [Research] SK hynix (000660 / SKHY) – Daishin | Capex Discipline · Multi-Year LTA · Shareholder Returns / 2026-01-30 Research
  • [Research] LigaChem Biosciences (141080) – Shinhan Securities | ConjuALL · Clinical Milestones · Big Pharma L/O / 2026-03-24 Research

[Research] Samsung SDI (006400) – iM Securities | AIDC ESS Demand · US Regulation Benefits · Medium- to Long-Term Growth / 2026-05-11

Posted on May 11, 2026August 22, 2026 By ksb220805@gmail.com

Brokerage : iM Securities

Analyst : Won-seok Jung

Investment Rating : Buy (Maintained)

Target Price : KRW 800,000 (Maintained)

Core Momentum : Surging AI data center power requirements and intensifying US regulatory restrictions on Chinese batteries are set to drive North American ESS market share gains and secure medium- to long-term growth.

📊 1. [Valuation & Key Financial Metrics]

  • Investment Rating & Target Price: Buy (Maintained), Target Price KRW 800,000 (Maintained)
  • Market Data (As of 2026-05-08): Close KRW 678,000 (Upside Potential 18.0%), Market Cap KRW 54.64 Trillion, Capital Stock KRW 416.0 Billion, Shares Outstanding 80.59 Million, Foreign Ownership 25.5%
  • Key Financial Forecasts (2025 → 2026F → 2027F → 2028F):
    • Revenue: KRW 13.27 Trillion → KRW 15.66 Trillion → KRW 19.94 Trillion → KRW 22.97 Trillion
    • Operating Profit: KRW -1.998 Trillion → KRW 24.0 Billion (Turnaround) → KRW 1.43 Trillion → KRW 2.26 Trillion
    • Net Profit: KRW -649.0 Billion → KRW -38.0 Billion (Loss Reduced) → KRW 1.18 Trillion (Turnaround) → KRW 1.73 Trillion
    • EPS: KRW -8,325 → KRW -468 → KRW 14,325 → KRW 21,058
    • BPS: KRW 260,851 → KRW 269,571 → KRW 293,105 → KRW 323,362
    • ROE: -3.2% → -0.2% → 5.1% → 6.8%
    • PER / PBR: -x / 1.0x → -x / 2.5x → 47.3x / 2.3x → 32.2x / 2.1x
    • EV/EBITDA: 293.8x → 24.2x → 15.4x → 12.0x

🚀 2. [Market Opportunities & Business Outlook]

  • Surging AI Data Center (AIDC) ESS Demand:
    • Structural Expansion: Driven by load leveling, upstream grid protection, and power quality management, global AIDC ESS battery shipments are forecast to surge from ~12GWh in 2025 to ~61GWh in 2027 and ~272GWh by 2030.
    • Rising Adoption Share: The share of AIDC applications within total global ESS demand is projected to expand rapidly from ~5% in 2025 to ~31% by 2030.
    • ESS Segment Projections: ESS revenue and operating profit are projected to expand significantly from KRW 2.9 Trillion (YoY +16%) and KRW 24.8 Billion (YoY -79%) in 2025 to KRW 9.2 Trillion (YoY +15%) and KRW 1.7 Trillion (YoY +16%) by 2028, emerging as the core pillar of earnings growth.
  • Industry Dynamics & Valuation Context:
    • Priced-in EV Headwinds: Concerns surrounding US EV tax credit expirations and heightened competition in Europe from Chinese cell makers have largely been priced into historical share price and EPS estimate corrections since 1H23.
    • Policy Tailwinds: Intensifying US regulations on Chinese ESS batteries from 2026 offer structural market share growth opportunities for Korean cell makers focusing on the US market. The stock trades at a 2028F P/E of 32.3x (reflecting a premium over the global peer average of 22.6x), indicating near-term upside may be capped and suggesting a buy-on-dips trading approach.

📝 Editor’s Comment (Perspective)

The analyst views Samsung SDI as a battery manufacturer that has already reflected major EV end-market headwinds into its valuation, positioning itself to capture medium- to long-term growth by pivoting toward AI data center power demand and capitalizing on US trade restrictions. This perspective highlights the strategic transition where ESS evolves from basic surplus power storage into critical infrastructure for hyperscale computing, serving as the central driver of corporate earnings expansion.

To verify the ongoing validity of this investment thesis, key monitoring factors include market share gains in North America as US regulatory restrictions on Chinese ESS intensify from 2026, new contract wins with US data center customers, and the operational trajectory toward achieving the projected KRW 1.7 Trillion in ESS operating profit by 2028. These fundamental milestones can be tracked through upcoming quarterly earnings releases, official company IR presentations, and periodic regulatory filings.

📢 Disclaimer & Source

Source: This content has been structured and newly written based on officially disclosed financial facts and data from brokerage reports.

Investment Risk Notice: This content is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific securities. All investment decisions and financial responsibilities rest entirely with the investor.

Contact: Compliance and Copyright Inquiries (ksb220805@gmail.com)

Search by
Company Name or Stock Ticker.
Research, EV & Battery

Post navigation

Previous Post: [Research] LIG D&A (079550) – Kiwoom Securities | Expanding Order Opportunities · 1Q26 Earnings Beat · Global Air Defense Growth / 2026-05-08
Next Post: [Research] SK hynix (000660 / SKHY) – Kiwoom | Commodity Memory Pricing · Supply Constraints · Earnings Surge / 2026-05-11

Related Posts

  • [Research] LIG D&A (079550) – Yuanta Securities | Cheongung-II Demand Surge · OPM Guidance Upgrade · Middle East Overlap / 2026-08-07 Research
  • [Research] SK hynix (000660 / SKHY) – Mirae Asset | Memory Pricing Resilience · Earnings Visibility · Valuation Appeal / 2026-04-01 Research
  • [Research] SK hynix (000660 / SKHY) – Hyundai Motor | LTA · Premium Product Mix · Blended ASP / 2026-07-14 Research
  • [Research] Samsung Biologics (207940) – Mirae Asset | Plant 5 Ramp-up · CDMO Expansion · Earnings Forecast / 2026-07-27 Research
  • [Research] ABL Bio (298380) – Yuanta Securities | Givastomig Efficacy · Bispecific ADC · Platform Valuation / 2026-01-29 Research
  • [Research] LIG D&A (079550) – Hana Securities | Complementing Patriot · Cheongung-II Cost Competitiveness · KRW 26.2T Backlog / 2026-03-03 Research
  • [Research] Samsung Biologics (207940) – Shinhan Securities | Capacity Expansion · Peptide Entry · Guidance Upgrade / 2026-07-24 Research
  • [Research] Samsung Electro-Mechanics (009150) – Kyobo Securities | AI Server Demand · High-Value Mix · Structural Profitability / 2026-07-31 Research
  • [Research] Alteogen (196170) – Hana Securities | Target Price Adjusted on Royalty Structure & Deal Assumptions · Deal Acceleration Starts in 2026 / 2026-01-22 Research
  • [IR] SK hynix (000660 / SKHY) – Q2 2026 Earnings Presentation / 2026-07-29 IR Room
  • [Research] Samsung Biologics (207940) – Kiwoom Securities | Plant 5 H2 Revenue Recognition · US Site Cost Control · 2026 Profitability Defense / 2026-01-07 Research
  • [Research] Celltrion (068270) – DS Investment & Securities | 2Q26 Re: Steep Growth Exceeds Expectations · New Biosimilars Surge · Large-Cap Top Pick / 2026-07-28 Research
  • [Research] SK hynix (000660 / SKHY) – Daishin | HBM4 · Memory Supply Shortage · Shareholder Returns / 2026-01-02 Research
  • [Research] Samsung Biologics (207940) – IBK Securities | US Operations · Plant 5 Ramp-up · Peptide Expansion / 2026-07-24 Research

Copyright © 2026 Korea Equity Lens.

Powered by PressBook News Dark theme